Life sciences securities litigation and enforcement issues

Video | May 18, 2016

Pharmaceutical, medical device and biotech companies are facing increasing scrutiny from the United States (US) Securities & Exchange Commission (SEC) and Department of Justice (DOJ), and have become a target for securities class action lawyers.
Last year, life sciences companies accounted for nearly one third of all US securities class actions filed. Given the increased focus on internal controls, it is more important than ever for these companies to understand the litigation and enforcement ramifications of their disclosure practices.

Please join us for a discussion regarding the impact of the current securities litigation and enforcement environment on life sciences companies.

Topics will include:

  • the recent speech by the SEC's Chief Accountant regarding enforcement priorities in the life sciences industry
  • the SEC's heightened focus on internal controls and financial reporting issues
  • the types of claims securities class action plaintiffs are asserting against life sciences companies
  • the current state of the law regarding the scope of a company's duty to disclose unfavorable information
  • the steps companies can take to improve their disclosure practices and minimize their securities litigation and enforcement risk
  • other new class action litigation risks, including classwide liability for unsolicited faxes to pharmacies

Download the presentation: Life sciences securities litigation and enforcement issues

*If you are viewing a recording of this web seminar, most state bar organizations will only allow you to claim self-study CLE credit. Please refer to your state's CLE rules. If you have any questions regarding CLE approval of this course in your applicable bar, please contact your bar administrator.

Contacts

Robin Adelstein

Robin Adelstein

New York
Kevin James Harnisch

Kevin James Harnisch

Washington, DC